Author: admin

Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren’s syndrome

https://pubmed.ncbi.nlm.nih.gov/33025899/ https://www.ncbi.nlm.nih.gov/pubmed/33025899?dopt=Abstract TITLE: Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren’s syndrome. DESCRIPTION: Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren’s syndrome. Clin Exp Rheumatol. 2020 Sep 25; Authors: Vehof J, Utheim TP, Bootsma H, Hammond CJ Abstract Primary Sjögren’s syndrome […]

Blockade of Th17 response by IL-38 in primary Sjögren’s syndrome

https://www.sciencedirect.com/science/article/pii/S016158902030482X?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/32950755?dopt=Abstract TITLE: Blockade of Th17 response by IL-38 in primary Sjögren’s syndrome. DESCRIPTION: Blockade of Th17 response by IL-38 in primary Sjögren’s syndrome. Mol Immunol. 2020 Sep 17;127:107-111 Authors: Luo D, Chen Y, Zhou N, Li T, Wang H Abstract BACKGROUND: T helper 17 (Th17) cell responses were involved in the pathophysiology of primary […]

Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients

https://clinicaltrials.gov/ct2/show/NCT04546542?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F31%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients DESCRIPTION: Condition:   Sjogren’s SyndromeIntervention:   Other: Parallel AssignmentSponsor:   University of Sao Paulo General HospitalNot yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT04546542 FIRST POSTED: Mon, 14 Sep 2020 12:00:00 EDT LAST UPDATE POSTED: 09/14/20 07:10AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT04546542?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F31%2F2020&lupd_d=14&sort=nwst

CP-25, a compound derived from paeoniflorin: research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases

https://www.nature.com/articles/s41401-020-00510-6 https://www.ncbi.nlm.nih.gov/pubmed/32884075?dopt=Abstract TITLE: CP-25, a compound derived from paeoniflorin: research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases. DESCRIPTION: Related Articles CP-25, a compound derived from paeoniflorin: research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases. Acta Pharmacol Sin. 2020 Sep […]

Understanding the Complexity of Sjögren’s Syndrome: Remarkable Progress in Elucidating NF-κB Mechanisms

https://www.mdpi.com/2077-0383/9/9/2821/htm https://www.ncbi.nlm.nih.gov/pubmed/32878252?dopt=Abstract TITLE: Understanding the Complexity of Sjögren’s Syndrome: Remarkable Progress in Elucidating NF-κB Mechanisms. DESCRIPTION: Related Articles Understanding the Complexity of Sjögren’s Syndrome: Remarkable Progress in Elucidating NF-κB Mechanisms. J Clin Med. 2020 Aug 31;9(9): Authors: Sisto M, Ribatti D, Lisi S Abstract Sjögren’s syndrome (SS) is a systemic autoimmune inflammatory disease with a […]

Adjuvant rituximab improves sensory ataxia in CIDP-related Sjögren syndrome

https://casereports.bmj.com/content/13/8/e234681 https://www.ncbi.nlm.nih.gov/pubmed/32847874?dopt=Abstract TITLE: Adjuvant rituximab improves sensory ataxia in CIDP-related Sjögren syndrome. DESCRIPTION: Related Articles Adjuvant rituximab improves sensory ataxia in CIDP-related Sjögren syndrome. BMJ Case Rep. 2020 Aug 26;13(8): Authors: Rocha R, Correia F, Santos A, Martins J Abstract Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune neuropathy characterised by insidious onset, progressive course, […]

TrueTear in Sjogren’s Disease Patients

https://clinicaltrials.gov/ct2/show/NCT03719885?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F11%2F2020&lupd_d=14&sort=nwst STUDY TITLE: TrueTear in Sjogren’s Disease Patients DESCRIPTION: Conditions:   Dry Eye Syndromes;   Sjogren’s SyndromeIntervention:   Device: TrueTear Intranasal Tear NeurostimulatorSponsors:   University of Pennsylvania;   AllerganCompleted CLINICALTRIALS.GOV IDENTIFIER: NCT03719885 FIRST POSTED: Thu, 25 Oct 2018 12:00:00 EDT LAST UPDATE POSTED: 08/25/20 07:09AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT03719885?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F11%2F2020&lupd_d=14&sort=nwst

MicroRNAs and Autoimmune-Mediated Eye Diseases

https://www.frontiersin.org/articles/10.3389/fcell.2020.00818/full https://www.ncbi.nlm.nih.gov/pubmed/32974350?dopt=Abstract TITLE: MicroRNAs and Autoimmune-Mediated Eye Diseases. DESCRIPTION: Related Articles MicroRNAs and Autoimmune-Mediated Eye Diseases. Front Cell Dev Biol. 2020;8:818 Authors: Wei Y, Li N, Zhao L, Yang C, Ma B, Li X, Wei R, Nian H Abstract MicroRNAs (miRNAs) are evolutionarily conserved short non-coding RNAs that act at post-transcriptional regulation of gene expression […]

The applications of androgen in the treatment of dry eye disease: a systematic review of clinical studies

https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ20-0178/_article https://www.ncbi.nlm.nih.gov/pubmed/32814731?dopt=Abstract TITLE: The applications of androgen in the treatment of dry eye disease: a systematic review of clinical studies. DESCRIPTION: Related Articles The applications of androgen in the treatment of dry eye disease: a systematic review of clinical studies. Endocr J. 2020 Aug 18;: Authors: Wang L, Deng Y Abstract Androgen regulates the function […]

Nuclease Therapy Improves Severe Fatigue in Primary Sjögren’s Syndrome: A Randomized Clinical Trial

https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41489 https://www.ncbi.nlm.nih.gov/pubmed/32798283?dopt=Abstract TITLE: Nuclease Therapy Improves Severe Fatigue in Primary Sjögren’s Syndrome: A Randomized Clinical Trial. DESCRIPTION: Nuclease Therapy Improves Severe Fatigue in Primary Sjögren’s Syndrome: A Randomized Clinical Trial. Arthritis Rheumatol. 2020 Aug 15;: Authors: Posada J, Valadkhan S, Burge D, Davies K, Tarn J, Casement J, Jobling K, Gallagher P, Wilson D, Barone […]

Ask the Expert: CBD Oil and Sjögren’s

https://www.sjogrens.org/blog/2020/ask-the-expert-cbd-oil-and-sjogrens Ask the Expert: CBD Oil and Sjögren’s Ask the Expert, Symptoms, Treatment — Aug 12, 2020

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT03905525?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F14%2F2019&lupd_d=14&sort=nwst STUDY TITLE: Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren’s Syndrome DESCRIPTION: Condition:   Sjögren SyndromeInterventions:   Drug: CFZ533;   Other: PlaceboSponsor:   Novartis PharmaceuticalsRecruiting CLINICALTRIALS.GOV IDENTIFIER: NCT03905525 FIRST POSTED: Fri, 05 Apr 2019 12:00:00 EDT LAST UPDATE POSTED: 10/28/19 11:40AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT03905525?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F14%2F2019&lupd_d=14&sort=nwst

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F21%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome Phase Ib-IIa Placebo-Controlled Clinical Trial and Associated Mechanistic Studies DESCRIPTION: Condition:   Sjogren’s SyndromeInterventions:   Drug: tofacitinib;   Other: PlaceboSponsor:   National Institute of Dental and Craniofacial Research (NIDCR)Not yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT04496960 FIRST POSTED: Tue, 04 Aug 2020 12:00:00 EDT […]

Involvement of Immune Cells Derived From the Intestine in Sjogren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT03841318?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F09%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Involvement of Immune Cells Derived From the Intestine in Sjogren’s Syndrome DESCRIPTION: Condition:   Sjogren’s SyndromeInterventions:   Biological: blood sample;   Biological: biopsy of the labial salivary glandSponsor:   University Hospital, BordeauxNot yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT03841318 FIRST POSTED: Fri, 15 Feb 2019 12:00:00 EST LAST UPDATE POSTED: 03/23/20 12:38PM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT03841318?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F09%2F2020&lupd_d=14&sort=nwst

Chinese herbal medicine SS-1 inhibits T cell activation and abrogates TH responses in Sjögren’s syndrome

https://www.sciencedirect.com/science/article/pii/S0929664620303363?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/32741737?dopt=Abstract TITLE: Chinese herbal medicine SS-1 inhibits T cell activation and abrogates TH responses in Sjögren’s syndrome. DESCRIPTION: Related Articles Chinese herbal medicine SS-1 inhibits T cell activation and abrogates TH responses in Sjögren’s syndrome. J Formos Med Assoc. 2020 Jul 30;: Authors: Lee GA, Chang CM, Wu YC, Ma RY, Chen CY, Hsue […]

Intravenous Immunoglobulins for the Treatment of Primary Sjögren’s Syndrome Associated Painful Sensory Neuropathies

https://clinicaltrials.gov/ct2/show/NCT03700138?type=Intr https://clinicaltrials.gov/ct2/show/NCT03700138?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F13%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Intravenous Immunoglobulins for the Treatment of Primary Sjögren’s Syndrome Associated Painful Sensory Neuropathies DESCRIPTION: Condition:   Primary Sjögren’s Syndrome Painful Sensory NeuropathiesInterventions:   Drug: Privigen® 100mg/ml at the dose of 2g/kg of body weight;   Drug: NaCl 0,9%Sponsor:   University Hospital, Strasbourg, FranceRecruiting CLINICALTRIALS.GOV IDENTIFIER: NCT03700138 FIRST POSTED: Tue, 09 Oct 2018 12:00:00 EDT LAST UPDATE […]

Mesenchymal Stem Cell Therapy for Oral Inflammatory Diseases: Research Progress and Future Perspectives

https://www.eurekaselect.com/184122/article https://www.ncbi.nlm.nih.gov/pubmed/32713335?dopt=Abstract TITLE: Mesenchymal Stem Cell Therapy for Oral Inflammatory Diseases: Research Progress and Future Perspectives. DESCRIPTION: Related Articles Mesenchymal Stem Cell Therapy for Oral Inflammatory Diseases: Research Progress and Future Perspectives. Curr Stem Cell Res Ther. 2020 Jul 26;: Authors: Gong W, Wang F, He Y, Heath B, Zeng X, Zhang D, Chen Q […]

Injection of CD40 DNA vaccine ameliorates the autoimmune pathology of Non-obese Diabetic Mice with Sjögren’s Syndrome

https://www.sciencedirect.com/science/article/abs/pii/S0165247820303539?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/32707129?dopt=Abstract TITLE: Injection of CD40 DNA vaccine ameliorates the autoimmune pathology of Non-obese Diabetic Mice with Sjögren’s Syndrome. DESCRIPTION: Related Articles Injection of CD40 DNA vaccine ameliorates the autoimmune pathology of Non-obese Diabetic Mice with Sjögren’s Syndrome. Immunol Lett. 2020 Jul 21;: Authors: Zhou YB, Yuan X, Wang QK, Zhang H, Wang GS, Li […]

Current State of Knowledge on Primary Sjögren’s Syndrome, an Autoimmune Exocrinopathy

https://www.mdpi.com/2077-0383/9/7/2299 https://www.ncbi.nlm.nih.gov/pubmed/32698400?dopt=Abstract TITLE: Current State of Knowledge on Primary Sjögren’s Syndrome, an Autoimmune Exocrinopathy. DESCRIPTION: Related Articles Current State of Knowledge on Primary Sjögren’s Syndrome, an Autoimmune Exocrinopathy. J Clin Med. 2020 Jul 20;9(7): Authors: Parisis D, Chivasso C, Perret J, Soyfoo MS, Delporte C Abstract Primary Sjögren’s syndrome (pSS) is a chronic systemic autoimmune […]

Long-term hydroxychloroquine therapy improves the quality of sleep in patients with primary Sjögren’s syndrome: a real-world study [PDF]

http://apm.amegroups.com/article/view/47479/pdf https://www.ncbi.nlm.nih.gov/pubmed/32692242?dopt=Abstract TITLE: Long-term hydroxychloroquine therapy improves the quality of sleep in patients with primary Sjögren’s syndrome: a real-world study. DESCRIPTION: Related Articles Long-term hydroxychloroquine therapy improves the quality of sleep in patients with primary Sjögren’s syndrome: a real-world study. Ann Palliat Med. 2020 Jul 20;: Authors: Guan P, Sun C, Chen Z, Chen J, […]

Lung Involvement in Primary Sjögren’s Syndrome-An Under-Diagnosed Entity

https://www.frontiersin.org/articles/10.3389/fmed.2020.00332/full https://www.ncbi.nlm.nih.gov/pubmed/32766261?dopt=Abstract TITLE: Lung Involvement in Primary Sjögren’s Syndrome-An Under-Diagnosed Entity. DESCRIPTION: Related Articles Lung Involvement in Primary Sjögren’s Syndrome-An Under-Diagnosed Entity. Front Med (Lausanne). 2020;7:332 Authors: Sogkas G, Hirsch S, Olsson KM, Hinrichs JB, Thiele T, Seeliger T, Skripuletz T, Schmidt RE, Witte T, Jablonka A, Ernst D Abstract Interstitial lung disease (ILD) represents […]

Novel Cytokine Multiplex Assay for Tear Fluid Analysis in Sjogren’s Syndrome

https://www.tandfonline.com/doi/abs/10.1080/09273948.2020.1767792?journalCode=ioii20 https://www.ncbi.nlm.nih.gov/pubmed/32657632?dopt=Abstract TITLE: Novel Cytokine Multiplex Assay for Tear Fluid Analysis in Sjogren’s Syndrome. DESCRIPTION: Novel Cytokine Multiplex Assay for Tear Fluid Analysis in Sjogren’s Syndrome. Ocul Immunol Inflamm. 2020 Jul 13;:1-6 Authors: Willems B, Tong L, Minh TDT, Pham ND, Nguyen XH, Zumbansen M Abstract PURPOSE: Sjögren’s syndrome (SS) is an autoimmune disease associated […]

Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome

https://www.einnews.com/pr_news/521168729/luminary-therapeutics-and-case-western-reserve-university-enter-formal-collaboration-for-development-of-baff-car Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome MINNEAPOLIS, MN, USA, July 7, 2020 /EINPresswire.com/ — Luminary Therapeutics (Luminary Tx) and […]

The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases such as Sjogren’s Syndrome

https://www.eurekaselect.com/183529/article https://www.ncbi.nlm.nih.gov/pubmed/32634079?dopt=Abstract TITLE: The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. DESCRIPTION: The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. Curr Pharm Des. 2020 Jul 07;: Authors: Martinez GP, Zabaleta ME, Di Giulio C, Charris JE, Mijares MR Abstract Chloroquine (CQ) and hydroxychloroquine (HCQ) are derivatives of the heterocyclic […]

Study identifies CP-25 as a potential drug for the treatment of primary Sjögren’s syndrome

New research published in Nature’s Laboratory Investigation shows that CP-25 “increased saliva flow, alleviated the salivary gland indexes, and improved tissue integrity” in a mouse model of primary Sjogren’s syndrome. Researchers “identified the underlying mechanisms of the therapeutic effect of CP-25 and provided an experimental foundation for CP-25 as a potential drug in the treatment […]

CP-25 alleviates antigen-induced experimental Sjögren’s syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration

https://www.nature.com/articles/s41374-020-0453-0 https://www.ncbi.nlm.nih.gov/pubmed/32620868?dopt=Abstract TITLE: CP-25 alleviates antigen-induced experimental Sjögren’s syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration. DESCRIPTION: Related Articles CP-25 alleviates antigen-induced experimental Sjögren’s syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration. Lab Invest. 2020 Jul 03;: Authors: Wu H, Chen X, Gu F, Zhang P, Xu […]

M3 muscarinic acetylcholine receptor reactive Th17 cells in primary Sjögren’s syndrome

https://insight.jci.org/articles/view/135982 https://www.ncbi.nlm.nih.gov/pubmed/32614803?dopt=Abstract TITLE: M3 muscarinic acetylcholine receptor reactive Th17 cells in primary Sjögren’s syndrome. DESCRIPTION: M3 muscarinic acetylcholine receptor reactive Th17 cells in primary Sjögren’s syndrome. JCI Insight. 2020 Jul 02;: Authors: Abe S, Tsuboi H, Kudo H, Asashima H, Ono Y, Honda F, Takahashi H, Yagishita M, Hagiwara S, Kondo Y, Matsumoto I, Sumida […]

Iguratimod treatment reduces disease activity in early primary Sjögren’s syndrome

https://www.tandfonline.com/doi/abs/10.1080/14397595.2020.1789335?journalCode=imor20 https://www.ncbi.nlm.nih.gov/pubmed/32613869?dopt=Abstract TITLE: Iguratimod treatment reduces disease activity in early primary Sjögren’s syndrome: an open-label pilot study. DESCRIPTION: Iguratimod treatment reduces disease activity in early primary Sjögren’s syndrome: an open-label pilot study. Mod Rheumatol. 2020 Jul 02;:1-13 Authors: Chen H, Qi X, Li Y, Wu Q, Shi Q, Wang L, Li J, Zhao L, Zhang […]

Sjogren’s Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports

https://www.cureus.com/articles/28039-sjogrens-syndrome-and-clinical-benefits-of-low-dose-naltrexone-therapy-additional-case-reports https://www.ncbi.nlm.nih.gov/pubmed/32765993?dopt=Abstract TITLE: Sjogren’s Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports. DESCRIPTION: Related Articles Sjogren’s Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports. Cureus. 2020 Jul 01;12(7):e8948 Authors: Zashin S Abstract Sjogren’s syndrome (SS) is a chronic autoimmune disorder that causes the inflammation of the lacrimal and salivary glands, […]

The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients

https://link.springer.com/article/10.1007%2Fs10792-020-01490-6 https://www.ncbi.nlm.nih.gov/pubmed/32607949?dopt=Abstract TITLE: The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients. DESCRIPTION: Related Articles The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients. Int Ophthalmol. 2020 Jul 01;: Authors: Jiang W, Zhang L, Zhao Y, He X, Hu C, Liu Y Abstract PURPOSE: Primary Sjögren’s syndrome […]

Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sjögren’s syndrome

https://link.springer.com/article/10.1007%2Fs00415-020-10033-z https://www.ncbi.nlm.nih.gov/pubmed/32613444?dopt=Abstract TITLE: Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sjögren’s syndrome. DESCRIPTION: Related Articles Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sjögren’s syndrome. J Neurol. 2020 Jul 01;: Authors: Pindi Sala T, Villedieu M, Damian L, Crave JC, Pautot V, Stojanovich L, Tervaert JWC, Cherin P, Belizna C […]

Insight into Salivary Gland Aquaporins: AQP5 represents a potential therapeutic target for the treatment of xerostomia (dry mouth)

https://www.mdpi.com/2073-4409/9/6/1547 https://www.ncbi.nlm.nih.gov/pubmed/32630469?dopt=Abstract TITLE: Insight into Salivary Gland Aquaporins. DESCRIPTION: Related Articles Insight into Salivary Gland Aquaporins. Cells. 2020 Jun 25;9(6): Authors: D’Agostino C, Elkashty OA, Chivasso C, Perret J, Tran SD, Delporte C Abstract The main role of salivary glands (SG) is the production and secretion of saliva, in which aquaporins (AQPs) play a key […]

Characterization of antiapoptotic microRNAs in primary Sjögren’s syndrome: potential targets for the treatment of pSS

https://onlinelibrary.wiley.com/doi/abs/10.1002/cbf.3569 https://www.ncbi.nlm.nih.gov/pubmed/32575162?dopt=Abstract TITLE: Characterization of antiapoptotic microRNAs in primary Sjögren’s syndrome. DESCRIPTION: Characterization of antiapoptotic microRNAs in primary Sjögren’s syndrome. Cell Biochem Funct. 2020 Jun 23;: Authors: Yang Y, Hou Y, Li J, Zhang F, Du Q Abstract During the development of primary Sjögren’s syndrome (pSS), aberrant expression of autoantigen is a hallmark event. To […]

Identification of novel genes associated with dysregulation of B cells in patients with primary Sjögren’s syndrome

https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-02248-2 Research article Open Access Published: 22 June 2020 Identification of novel genes associated with dysregulation of B cells in patients with primary Sjögren’s syndrome Abstract Background The aim of this study was to identify the molecular mechanism of dysregulation of B cell subpopulations of primary Sjögren’s syndrome (pSS) at the transcriptome level. Methods We […]

Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases including Sjögren syndrome (SjS)

https://link.springer.com/article/10.1007%2Fs12016-020-08798-2 https://www.ncbi.nlm.nih.gov/pubmed/32557263?dopt=Abstract TITLE: Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases. DESCRIPTION: Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases. Clin Rev Allergy Immunol. 2020 Jun 17;: Authors: Jiang J, Zhao M, Chang C, Wu H, Lu Q Abstract Type I interferons (IFN-Is) are a very important group of […]

Association of salivary inflammatory biomarkers with primary Sjögren’s syndrome

https://onlinelibrary.wiley.com/doi/abs/10.1111/jop.13070 https://www.ncbi.nlm.nih.gov/pubmed/32538490?dopt=Abstract TITLE: Association of salivary inflammatory biomarkers with primary Sjögren’s syndrome. DESCRIPTION: Related Articles Association of salivary inflammatory biomarkers with primary Sjögren’s syndrome. J Oral Pathol Med. 2020 Jun 15;: Authors: Moreno-Quispe LA, Serrano J, Virto L, Sanz M, Ramírez L, Fernández-Castro M, Hernández G, López-Pintor RM Abstract BACKGROUND: Primary Sjogren’s syndrome (pSS) is […]

Total glucosides of paeony (TGP) alleviates constipation and intestinal inflammation in mice induced by Sjögren’s syndrome

https://www.sciencedirect.com/science/article/abs/pii/S0378874120314264?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/32525066?dopt=Abstract TITLE: Total glucosides of paeony (TGP) alleviates constipation and intestinal inflammation in mice induced by Sjögren’s syndrome. DESCRIPTION: Total glucosides of paeony (TGP) alleviates constipation and intestinal inflammation in mice induced by Sjögren’s syndrome. J Ethnopharmacol. 2020 Jun 07;:113056 Authors: Liu G, Wang Z, Li X, Liu R, Li B, Huang L, Chen […]

Fecal Microbial Transplant (FMT) for Sjogren’s Syndrome [Completed]

https://www.clinicaltrials.gov/ct2/show/NCT03926286?type=Intr&cond=Sjogren%27s+Syndrome&sort=nwst&draw=2&rank=9 Fecal Microbial Transplant (FMT) for Sjogrens Syndrome Study Description Go to sections Brief Summary: This is an open label study to evaluate the effect of Fecal Microbiota Transplantation (FMT) on the gut microbiome and Systemic parameters. Condition or disease Intervention/treatment Phase Sjogren’s Syndrome Drug: FMP-30 Phase 1 Study Design Go to sections Study Type […]

Safety and Efficacy of VAY736 in Patients With Primary Sjogren’s Syndrome (pSS)

https://www.clinicaltrials.gov/ct2/show/NCT02962895 Safety and Efficacy of VAY736 in Patients With Primary Sjogren’s Syndrome (pSS) Brief Summary: This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters Condition or disease Intervention/treatment Phase Primary Sjogren Syndrome Biological: VAY736 Other: Placebo Phase 2 Study Design Go to sections Study Type : Interventional (Clinical Trial) […]

Efficacy of Belimumab in Primary Sjögren’s Syndrome: A Systematic Review

https://www.sciencedirect.com/science/article/pii/S1699258X20300760?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/32451263?dopt=Abstract TITLE: Efficacy of Belimumab in Primary Sjögren’s Syndrome: A Systematic Review. DESCRIPTION: Related Articles Efficacy of Belimumab in Primary Sjögren’s Syndrome: A Systematic Review. Reumatol Clin. 2020 May 22;: Authors: Álvarez-Rivas N, Sang-Park H, Díaz Del Campo P, Fernández-Castro M, Corominas H, Andreu JL, Navarro-Compán V Abstract OBJECTIVE: To evaluate the efficacy and […]

Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren’s Syndrome

https://www.mdpi.com/2077-0383/9/5/1482 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290729/ https://www.ncbi.nlm.nih.gov/pubmed/32423153?dopt=Abstract TITLE: Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren’s Syndrome. DESCRIPTION: Related Articles Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren’s Syndrome. J Clin Med. 2020 May 14;9(5): Authors: Butryn M, Neumann J, Rolfes L, Bartels C, Wattjes MP, Mahmoudi N, Seeliger T, Konen […]

Immunobiology of T Cells in Sjögren’s Syndrome: summary of research progress to provide insights for clinical treatment

https://link.springer.com/article/10.1007/s12016-020-08793-7 https://www.ncbi.nlm.nih.gov/pubmed/32390096?dopt=Abstract TITLE: Immunobiology of T Cells in Sjögren’s Syndrome. DESCRIPTION: Immunobiology of T Cells in Sjögren’s Syndrome. Clin Rev Allergy Immunol. 2020 May 11;: Authors: Yao Y, Ma JF, Chang C, Xu T, Gao CY, Gershwin ME, Lian ZX Abstract Sjögren’s syndrome (SjS) is a systemic autoimmune disease marked by xerostomia (dry mouth), keratoconjunctivitis […]

Fibromyalgia, Sjogren’s & Depression: Linked?

https://www.tandfonline.com/doi/abs/10.1080/00325481.2020.1758426?journalCode=ipgm20 https://www.ncbi.nlm.nih.gov/pubmed/32314938?dopt=Abstract TITLE: Fibromyalgia, Sjogren’s & Depression: Linked? DESCRIPTION: Fibromyalgia, Sjogren’s & Depression: Linked? Postgrad Med. 2020 Apr 21;: Authors: Loganathan M, Ladani A, Lippmann S Abstract Health care has become increasingly fragmented, partly due to advancing medical technology. Patients are often managed by various specialty teams when presenting with symptoms that could be manifestations […]

Cysteine cathepsins as therapeutic targets in inflammatory diseases

https://www.tandfonline.com/doi/abs/10.1080/14728222.2020.1746765 Cysteine cathepsins as therapeutic targets in inflammatory diseases Matej Vizovišek,Eva Vidak,Urban Javoršek,Georgy Mikhaylov,Andreja Bratovš &Boris Turk Pages 573-588 | Received 23 Dec 2019, Accepted 20 Mar 2020, Accepted author version posted online: 31 Mar 2020, Published online: 06 Apr 2020 Download citation https://doi.org/10.1080/14728222.2020.1746765 CrossMark LogoCrossMark

Rebamipide for the Treatment of Xerostomia (Dry Mouth) in Sjögren Syndrome

https://clinicaltrials.gov/ct2/show/NCT01759108?type=Intr https://clinicaltrials.gov/ct2/show/NCT01759108?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F17%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Rebamipide AND Sjögren Syndrome DESCRIPTION: Condition:   Improving Symptoms of Dry Mouth in Sjőgren’s SyndromeIntervention:   Drug: RebamipideSponsor:   University of AlexandriaRecruiting CLINICALTRIALS.GOV IDENTIFIER: NCT01759108 FIRST POSTED: Wed, 02 Jan 2013 12:00:00 EST LAST UPDATE POSTED: 03/31/20 09:29AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT01759108?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F17%2F2020&lupd_d=14&sort=nwst

JAK Inhibitors: Prospects in Connective Tissue Diseases including Sjögren’s Syndrome

https://link.springer.com/article/10.1007/s12016-020-08786-6 https://www.ncbi.nlm.nih.gov/pubmed/32222877?dopt=Abstract TITLE: JAK Inhibitors: Prospects in Connective Tissue Diseases. DESCRIPTION: Related Articles JAK Inhibitors: Prospects in Connective Tissue Diseases. Clin Rev Allergy Immunol. 2020 Mar 28;: Authors: You H, Xu D, Zhao J, Li J, Wang Q, Tian X, Li M, Zeng X Abstract The dysregulation of the JAK-STAT pathway is associated with various […]

Pilot Trial of Ustekinumab for Primary Sjögren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT04093531?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst STUDY TITLE: Pilot Trial of Ustekinumab for Primary Sjögren’s Syndrome DESCRIPTION: Condition:   Primary Sjögren SyndromeIntervention:   Drug: UstekinumabSponsor:   University of RochesterNot yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT04093531 FIRST POSTED: Wed, 18 Sep 2019 12:00:00 EDT LAST UPDATE POSTED: 10/22/19 07:00AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT04093531?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst

Total glucosides of paeony (TGP) alleviates Sjogren’s syndrome through inhibiting inflammatory responses in mice

https://www.sciencedirect.com/science/article/abs/pii/S0944711320300362?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/32402913?dopt=Abstract TITLE: Total glucosides of paeony (TGP) alleviates Sjogren’s syndrome through inhibiting inflammatory responses in mice. DESCRIPTION: Total glucosides of paeony (TGP) alleviates Sjogren’s syndrome through inhibiting inflammatory responses in mice. Phytomedicine. 2020 Mar 06;71:153203 Authors: Li B, Liu G, Liu R, He S, Li X, Huang L, Wang Z, Li Y, Chen Y, […]

Depletion of ID3 enhances mesenchymal stem cells therapy by targeting BMP4 in Sjögren’s syndrome

https://www.nature.com/articles/s41419-020-2359-6 https://www.ncbi.nlm.nih.gov/pubmed/32139667?dopt=Abstract TITLE: Depletion of ID3 enhances mesenchymal stem cells therapy by targeting BMP4 in Sjögren’s syndrome. DESCRIPTION: Related Articles Depletion of ID3 enhances mesenchymal stem cells therapy by targeting BMP4 in Sjögren’s syndrome. Cell Death Dis. 2020 Mar 05;11(3):172 Authors: Hu L, Xu J, Wu T, Fan Z, Sun L, Liu Y, Li Y, […]

Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren’s syndrome

https://www.sciencedirect.com/science/article/pii/S1521694220300012?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/32067925?dopt=Abstract TITLE: Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren’s syndrome. DESCRIPTION: Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren’s syndrome. Best Pract Res Clin Rheumatol. 2020 Feb 15;:101485 Authors: van den Hoogen LL, van Laar JM Abstract Targeted therapies using biological disease-modifying antirheumatic drugs (bDMARDs) and small molecule synthetic […]

Wize Pharma Completes Patient Enrollment In Phase 4 Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome

https://www.prnewswire.com/news-releases/wize-pharma-completes-patient-enrollment-in-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome-300990264.html Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome – Topline Results Expected Q2 2020 – Study designed to support approval pathway in the U.S. and other major markets Jan 21, 2020, 09:00 ET HOD HASHARON, Israel, Jan. 21, 2020 […]

Mechanisms of Disease in Sjögren Syndrome-New Developments and Directions

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013496/ https://www.ncbi.nlm.nih.gov/pubmed/31963817?dopt=Abstract TITLE: Mechanisms of Disease in Sjögren Syndrome-New Developments and Directions. DESCRIPTION: Related Articles Mechanisms of Disease in Sjögren Syndrome-New Developments and Directions. Int J Mol Sci. 2020 Jan 19;21(2): Authors: de Paiva CS, Pflugfelder SC Abstract Sjögren Syndrome (SS) is an autoimmune disease that affects the exocrine glands, mainly salivary and lacrimal glands […]

Primary Sjogren’s syndrome: a great masquerader

https://casereports.bmj.com/content/12/12/e231802.full https://casereports.bmj.com/content/12/12/e231802 https://www.ncbi.nlm.nih.gov/pubmed/31888893?dopt=Abstract TITLE: Primary Sjogren’s syndrome: a great masquerader. DESCRIPTION: Related Articles Primary Sjogren’s syndrome: a great masquerader. BMJ Case Rep. 2019 Dec 29;12(12): Authors: Kumar N, Surendran D, Srinivas BH, Bammigatti C Abstract A 41-year-old woman presented with paresthesia and inability to walk for 7 days. She had history of fatigue, polyarthralgia and […]

A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren’s syndrome

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294338/ https://www.sciencedirect.com/science/article/pii/S0168365918306059?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/30359668?dopt=Abstract TITLE: A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren’s syndrome. DESCRIPTION: Related Articles A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren’s syndrome. J Control Release. 2018 12 28;292:183-195 Authors: Guo H, Lee […]

A213, a RORγt antagonist, improves Sjögren’s syndrome-like sialadenitis through downregulation of CD25

https://onlinelibrary.wiley.com/doi/abs/10.1111/odi.13255 https://www.ncbi.nlm.nih.gov/pubmed/31837283?dopt=Abstract TITLE: RORγt antagonist improves Sjögren’s syndrome-like sialadenitis through downregulation of CD25. DESCRIPTION: Related Articles RORγt antagonist improves Sjögren’s syndrome-like sialadenitis through downregulation of CD25. Oral Dis. 2020 May;26(4):766-777 Authors: Ono Y, Tsuboi H, Moriyama M, Asashima H, Kudo H, Takahashi H, Honda F, Abe S, Kondo Y, Takahashi S, Matsumoto I, Nakamura S, […]

Sjögren’s syndrome: Old and new therapeutic targets

https://www.sciencedirect.com/science/article/abs/pii/S0896841119307267 Sjögren’s syndrome: Old and new therapeutic targets Academy of Athens, Chair Medical Sciences/Immunology, Greece Received 6 November 2019, Accepted 10 November 2019, Available online 9 December 2019.

LncRNA PVT1 links Myc to glycolytic metabolism upon CD4+ T cell activation and Sjögren’s syndrome-like autoimmune response

https://www.sciencedirect.com/science/article/pii/S0896841119306006?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/31757716?dopt=Abstract TITLE: LncRNA PVT1 links Myc to glycolytic metabolism upon CD4+ T cell activation and Sjögren’s syndrome-like autoimmune response. DESCRIPTION: Related Articles LncRNA PVT1 links Myc to glycolytic metabolism upon CD4+ T cell activation and Sjögren’s syndrome-like autoimmune response. J Autoimmun. 2019 Nov 19;:102358 Authors: Fu J, Shi H, Wang B, Zhan T, Shao […]

Associations of Anti-Aquaporin 5 Autoantibodies with Features of Sjögren’s Syndrome: Screening may reveal subgroups of SS for targeted therapy

https://www.mdpi.com/2077-0383/8/11/1863 https://www.ncbi.nlm.nih.gov/pubmed/31684196?dopt=Abstract TITLE: Associations of Anti-Aquaporin 5 Autoantibodies with Serologic and Histopathological Features of Sjögren’s Syndrome. DESCRIPTION: Related Articles Associations of Anti-Aquaporin 5 Autoantibodies with Serologic and Histopathological Features of Sjögren’s Syndrome. J Clin Med. 2019 Nov 03;8(11): Authors: Jeon S, Lee J, Park SH, Kim HD, Choi Y Abstract Biomarkers to stratify the complex […]

Common and rare forms of vasculitis associated with Sjögren’s syndrome

https://www.ncbi.nlm.nih.gov/pubmed/31644467?dopt=Abstract TITLE: Common and rare forms of vasculitis associated with Sjögren’s syndrome. DESCRIPTION: Common and rare forms of vasculitis associated with Sjögren’s syndrome. Curr Opin Rheumatol. 2019 Oct 21;: Authors: Argyropoulou OD, Tzioufas AG Abstract PURPOSE OF REVIEW: Although uncommon, systemic vasculitis is one of the most severe extraglandular manifestations of primary Sjögren’s syndrome (pSS) […]

Primary Sjögren’s syndrome and the eye: update regarding pathogenesis, diagnosis, investigative procedures, and treatment options

https://www.surveyophthalmol.com/article/S0039-6257(19)30283-8/fulltext https://www.ncbi.nlm.nih.gov/pubmed/31634487?dopt=Abstract TITLE: Primary Sjögren’s syndrome and the eye. DESCRIPTION: Primary Sjögren’s syndrome and the eye. Surv Ophthalmol. 2019 Oct 18;: Authors: Bjordal O, Norheim KB, Rødahl E, Jonsson R, Omdal R Abstract Primary Sjögren syndrome is an autoimmune disease that mainly affects exocrine glands such as the salivary and lacrimal glands. In addition, systemic […]

A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren’s Syndrome [Completed]

https://www.clinicaltrials.gov/ct2/show/NCT04111341?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=09%2F17%2F2019&lupd_d=14&sort=nwst STUDY TITLE: A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren’s Syndrome. DESCRIPTION: Condition:   Sjögren’s SyndromeInterventions:   Drug: TCM (Gan-Lu-Yin)GLY;   Drug: PLACEBOSponsor:   Chung Shan Medical UniversityCompleted CLINICALTRIALS.GOV IDENTIFIER: NCT04111341 FIRST POSTED: Tue, 01 Oct 2019 12:00:00 EDT LAST UPDATE POSTED: 10/01/19 06:22PM STUDY LINK / URL: https://www.clinicaltrials.gov/ct2/show/NCT04111341?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=09%2F17%2F2019&lupd_d=14&sort=nwst

Immune checkpoint molecules: Possible future therapeutic implications in autoimmune diseases such as Sjögren’s syndrome

https://www.sciencedirect.com/science/article/abs/pii/S0896841119305712?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/31564474?dopt=Abstract TITLE: Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases. DESCRIPTION: Related Articles Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases. J Autoimmun. 2019 11;104:102333 Authors: Huang C, Zhu HX, Yao Y, Bian ZH, Zheng YJ, Li L, Moutsopoulos HM, Gershwin ME, Lian ZX Abstract During host immune response, an […]

An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren’s Syndrome

https://www.clinicaltrials.gov/ct2/show/NCT03627065 A Study of INCB050465 in Primary Sjögren’s Syndrome Brief Summary: The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren’s syndrome (SS). Condition or disease Intervention/treatment Phase Primary Sjögren’s Syndrome Drug: Parsaclisib Phase 2 Study Design Go to sections Study Type : Interventional Estimated Enrollment […]

Saliva microbiome in primary Sjögren’s syndrome reveals distinct set of disease-associated microbes

https://onlinelibrary.wiley.com/doi/abs/10.1111/odi.13191 https://www.ncbi.nlm.nih.gov/pubmed/31514257?dopt=Abstract TITLE: Saliva microbiome in primary Sjögren’s syndrome reveals distinct set of disease-associated microbes. DESCRIPTION: Related Articles Saliva microbiome in primary Sjögren’s syndrome reveals distinct set of disease-associated microbes. Oral Dis. 2020 Mar;26(2):295-301 Authors: Sharma D, Sandhya P, Vellarikkal SK, Surin AK, Jayarajan R, Verma A, Kumar A, Ravi R, Danda D, Sivasubbu S, […]

Biologics in Sjögren’s syndrome

https://www.sciencedirect.com/science/article/abs/pii/S1043661819310424?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/31415917?dopt=Abstract TITLE: Biologics in Sjögren’s syndrome. DESCRIPTION: Related Articles Biologics in Sjögren’s syndrome. Pharmacol Res. 2019 09;147:104389 Authors: Skarlis C, Marketos N, Mavragani CP Abstract The use of biologic disease modifying antirheumatic drugs (bDMARDs) in systemic autoimmune diseases such as rheumatoid arthritis and at a lesser extent in lupus, has been well established. In […]

Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome: CatS inhibition may represent a promising novel treatment strategy in pSS

https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1955-2 https://www.ncbi.nlm.nih.gov/pubmed/31319889?dopt=Abstract TITLE: Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome. DESCRIPTION: Related Articles Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome. Arthritis Res Ther. 2019 07 18;21(1):175 Authors: Hargreaves P, Daoudlarian D, Theron M, Kolb FA, Manchester Young M, Reis […]

Potential therapeutic applications of exosomes in different autoimmune diseases including Sjogren’s syndrome

https://www.sciencedirect.com/science/article/abs/pii/S1521661619301548?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/31228581?dopt=Abstract TITLE: Potential therapeutic applications of exosomes in different autoimmune diseases. DESCRIPTION: Related Articles Potential therapeutic applications of exosomes in different autoimmune diseases. Clin Immunol. 2019 08;205:116-124 Authors: Xu H, Jia S, Xu H Abstract Autoimmune diseases are caused by self-immune responses to autoantigens, which damage body tissues and severely affect the patient’s quality […]

Sjögren’s syndrome update: Clinical and therapeutic aspects

https://www.sciencedirect.com/science/article/abs/pii/S0248866319304242?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/31027874?dopt=Abstract TITLE: [Sjögren’s syndrome update: Clinical and therapeutic aspects]. DESCRIPTION: Related Articles [Sjögren’s syndrome update: Clinical and therapeutic aspects]. Rev Med Interne. 2019 Jul;40(7):433-439 Authors: Nocturne G Abstract Sjögren’s syndrome (SS) is a systemic orphan disease. It is characterized by the involvement of epithelial tissues leading to the term of autoimmune epithelitis. New classification […]

Sjögren’s Syndrome: Moisturize Me! – Reddit

https://www.reddit.com/r/Sjogrens/ Sjögren’s Syndrome: Moisturize Me! – Reddit r/Sjogrens: This is a space for people to discuss our struggles and successes with Sjögren’s. A place to share information and encourage each other.

Sjogren’s World Forums

http://sjogrensworld.org/forums/index.php http://sjogrensworld.org/forums/index.php?PHPSESSID=43342a14cd1951974f34f50303cffe96&board=1.0